JP2005502683A5 - - Google Patents

Download PDF

Info

Publication number
JP2005502683A5
JP2005502683A5 JP2003524991A JP2003524991A JP2005502683A5 JP 2005502683 A5 JP2005502683 A5 JP 2005502683A5 JP 2003524991 A JP2003524991 A JP 2003524991A JP 2003524991 A JP2003524991 A JP 2003524991A JP 2005502683 A5 JP2005502683 A5 JP 2005502683A5
Authority
JP
Japan
Prior art keywords
pyrrolo
propyl
dimethyl
pyrimidine
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003524991A
Other languages
English (en)
Japanese (ja)
Other versions
JP4629334B2 (ja
JP2005502683A (ja
Filing date
Publication date
Priority claimed from GBGB0121033.5A external-priority patent/GB0121033D0/en
Application filed filed Critical
Publication of JP2005502683A publication Critical patent/JP2005502683A/ja
Publication of JP2005502683A5 publication Critical patent/JP2005502683A5/ja
Application granted granted Critical
Publication of JP4629334B2 publication Critical patent/JP4629334B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003524991A 2001-08-30 2002-08-29 システインプロテアーゼの阻害因子としてのピロロピリミジン Expired - Fee Related JP4629334B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0121033.5A GB0121033D0 (en) 2001-08-30 2001-08-30 Organic compounds
PCT/EP2002/009663 WO2003020721A1 (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases

Publications (3)

Publication Number Publication Date
JP2005502683A JP2005502683A (ja) 2005-01-27
JP2005502683A5 true JP2005502683A5 (enExample) 2010-09-09
JP4629334B2 JP4629334B2 (ja) 2011-02-09

Family

ID=9921234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003524991A Expired - Fee Related JP4629334B2 (ja) 2001-08-30 2002-08-29 システインプロテアーゼの阻害因子としてのピロロピリミジン

Country Status (29)

Country Link
US (2) US7452886B2 (enExample)
EP (1) EP1423391B8 (enExample)
JP (1) JP4629334B2 (enExample)
KR (1) KR100695845B1 (enExample)
CN (1) CN100372849C (enExample)
AR (1) AR036374A1 (enExample)
AT (1) ATE326469T1 (enExample)
AU (1) AU2002333760B2 (enExample)
BR (1) BR0212226A (enExample)
CA (1) CA2458684C (enExample)
CY (1) CY1105573T1 (enExample)
DE (1) DE60211530T2 (enExample)
DK (1) DK1423391T3 (enExample)
EC (1) ECSP044998A (enExample)
ES (1) ES2262888T3 (enExample)
GB (1) GB0121033D0 (enExample)
HU (1) HUP0401301A3 (enExample)
IL (3) IL160367A0 (enExample)
MX (1) MXPA04001935A (enExample)
MY (1) MY157368A (enExample)
NO (1) NO328890B1 (enExample)
NZ (1) NZ531343A (enExample)
PE (1) PE20030418A1 (enExample)
PL (1) PL368280A1 (enExample)
PT (1) PT1423391E (enExample)
RU (1) RU2331644C2 (enExample)
TW (1) TWI297690B (enExample)
WO (1) WO2003020721A1 (enExample)
ZA (1) ZA200401042B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0220187D0 (en) * 2002-08-30 2002-10-09 Novartis Ag Organic compounds
CN102526079B (zh) 2002-09-24 2014-06-18 诺华股份有限公司 治疗脱髓鞘疾病的鞘氨醇-1-磷酸受体激动剂
AR043692A1 (es) * 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
GB0304640D0 (en) 2003-02-28 2003-04-02 Novartis Ag Organic compounds
JP4710606B2 (ja) * 2003-04-18 2011-06-29 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
EP1797883A3 (en) * 2003-04-28 2007-08-01 Novartis AG Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
MXPA05011593A (es) * 2003-04-28 2005-12-15 Novartis Ag Composicion farmaceutica que comprende un inhibidor de catepsina s y un opioide.
JP2006525336A (ja) * 2003-04-30 2006-11-09 エフ エム シー コーポレーション フェニル置換した環状誘導体
WO2005011703A1 (en) * 2003-08-04 2005-02-10 Akzo Nobel N.V. 2-cyano-1,3,5-triazine-4,6-diamine derivatives
EP1786816A4 (en) * 2003-09-10 2009-11-04 Virochem Pharma Inc SPIROHYDANTOIN COMPOUNDS AND METHODS FOR MODULATING CHEMOKINE RECEPTOR ACTIVITY
BRPI0507498A (pt) 2004-02-18 2007-07-10 Astrazeneca Ab composto, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir ativação de receptores de mglur 5
US20070197510A1 (en) * 2004-03-10 2007-08-23 Kazuyuki Ohmoto Nitriles and medicinal compositions containing the same as the active ingredient
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
WO2005111042A1 (en) * 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
US7951816B2 (en) 2004-08-27 2011-05-31 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
KR100651849B1 (ko) * 2005-02-01 2006-12-01 엘지전자 주식회사 세탁기
AU2006277678B2 (en) * 2005-08-05 2012-04-19 Hybrigenics Sa Novel cysteine protease inhibitors and their therapeutic applications
EP1933860A2 (en) 2005-09-01 2008-06-25 Ares Trading S.A. Treatment of optic neuritis
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
AR056720A1 (es) * 2005-10-26 2007-10-17 Smithkline Beecham Corp Compuesto de tiazol substtuido composicion farmaceuticamente que lo comprende y su uso para preparar un medicamento
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
WO2007067504A2 (en) * 2005-12-05 2007-06-14 Incyte Corporation Lactam compounds and methods of using the same
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
JP2010503656A (ja) 2006-09-13 2010-02-04 アストラゼネカ アクチボラグ スピロ−オキサゾリジノン化合物と代謝共役型グルタミン酸受容体ポテンシエーターとしてのその使用
TW200911803A (en) * 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
TW200934771A (en) 2007-10-19 2009-08-16 Astrazeneca Ab New compounds
EP2303250A1 (en) 2008-06-20 2011-04-06 Novartis AG Paediatric compositions for treating1 multiple sclerosis
TW201035094A (en) 2009-01-16 2010-10-01 Organon Nv 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
CN102482278B (zh) 2009-06-29 2015-04-22 因塞特公司 作为pi3k抑制剂的嘧啶酮类
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2519525A4 (en) 2009-12-30 2013-06-12 Arqule Inc SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS
US9115126B2 (en) 2010-01-15 2015-08-25 Merck Sharp & Dohme B.V. 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
AU2011311452B2 (en) 2010-10-06 2016-09-01 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
TWI648277B (zh) 2011-09-02 2019-01-21 美商英塞特控股公司 作為pi3k抑制劑之雜環基胺
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
CN104284895B (zh) * 2012-04-17 2016-08-31 安斯泰来制药株式会社 含氮双环式芳香族杂环化合物
CA2875918A1 (en) 2012-06-06 2013-12-12 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
HK1213946A1 (zh) 2012-10-12 2016-07-15 Inbiomotion S.L. 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
AU2014229505B2 (en) 2013-03-15 2020-02-27 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
ES2727904T3 (es) 2013-10-09 2019-10-21 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastatizante del hueso que se origina a partir de cáncer de mama
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
CA3285092A1 (en) 2015-02-27 2025-11-29 Incyte Holdings Corporation Salts of pi3k inhibitor and processes for their preparation
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2017203468A1 (en) 2016-05-25 2017-11-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
AU2018372762B2 (en) 2017-11-22 2025-08-21 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
EP3556760A1 (en) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
CN120053645A (zh) 2018-06-01 2025-05-30 因赛特公司 治疗pi3k相关病症的给药方案
EP3946332A1 (en) 2019-04-05 2022-02-09 Université de Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
EP4326721A1 (en) * 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
KR20240090633A (ko) * 2021-12-01 2024-06-21 에스티팜 주식회사 트리아졸로피리미디논 유도체의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1251074B (de) * 1960-11-02 1967-09-28 J R Geigy A -G , Basel (Schweiz) Selektives Herbizid
CH627919A5 (de) 1977-04-14 1982-02-15 Ciba Geigy Ag Herbizide mittel.
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
ES2109796T3 (es) * 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
US5683999A (en) * 1995-03-17 1997-11-04 The Dupont Merck Pharmaceutical Company Cyclic urea HIV protease inhibitors
ATE247469T1 (de) * 1995-06-07 2003-09-15 Pfizer Heterocyclische kondensierte pyrimidin-derivate
ES2202827T3 (es) * 1997-03-19 2004-04-01 ABBOTT GMBH & CO. KG Pirrolo(2,3-d)pirimidinas y su uso como inhibidores de la tirosina kinasa.
DE69934311D1 (de) * 1998-06-30 2007-01-18 Lilly Co Eli BICYCLISCHE sPLA 2-INHIBITOREN
PL346700A1 (en) * 1998-09-18 2002-02-25 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors
GEP20053479B (en) * 1999-12-10 2005-03-25 Pfizer Prod Inc Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
CA2402516A1 (en) * 2000-03-20 2001-09-27 Roopa Rai Non-amidine containing protease inhibitors
CN1657523A (zh) 2000-04-28 2005-08-24 田边制药株式会社 环状化合物

Similar Documents

Publication Publication Date Title
JP2005502683A5 (enExample)
RU2424242C2 (ru) Азолопиримидины в качестве ингибиторов активности каннабиноидного рецептора 1
RU2431635C2 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
RU2331644C2 (ru) Пирролопиримидины, обладающие свойствами ингибитора катепсина к, и способ их получения (варианты)
JP2015511245A5 (enExample)
ES2271221T3 (es) Derivados imidazo-pirimidina como ligandos para receptores gaba.
JP2004533454A5 (enExample)
CA2687035A1 (en) Amino-heterocyclic compounds
RU2412171C2 (ru) Новое соединение пиперазина и его применение в качестве ингибитора hcv полимеразы
JP2003531210A5 (enExample)
RU2006129324A (ru) Конденсированные гетероциклические соединения и их применение в качестве антагонистов метаботропных глутаматных рецепторов
RU2012136907A (ru) Модуляторы гамма-секретазы
JP2008506708A5 (enExample)
MX2010014136A (es) Nuevos derivados de fenilimidazola como inhibidores de la enzima pde10a.
JP2010511709A5 (enExample)
JP2017518326A5 (enExample)
JP2007523183A5 (enExample)
RU2005112447A (ru) Комбинационное лекарство
JP2004525149A5 (enExample)
CA2407094A1 (en) Diazabicyclic central nervous system active agents
JP2013519707A5 (enExample)
JP2013500975A5 (enExample)
JPWO2020005873A5 (enExample)
HRP20121022T1 (hr) Kondenzirani bicikliäśki pirimidini
JP2007526285A5 (enExample)